<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14	CLINICAL STUDIES<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.1	Multiple Myeloma<BR>                     <BR>                        Two randomized studies (Studies 1 and 2) were conducted to evaluate the efficacy and safety of REVLIMID. These multicenter, multinational, double-blind, placebo-controlled studies compared REVLIMID plus oral pulse high-dose dexamethasone therapy to dexamethasone therapy alone in patients with multiple myeloma who had received at least one prior treatment. These studies enrolled patients with absolute neutrophil counts (ANC) ≥ 1000/mm3 platelet counts ≥ 75,000/mm3, serum creatinine ≤ 2.5 mg/dL, serum SGOT/AST or SGPT/ALT ≤ 3.0 x upper limit of normal (ULN), and serum direct bilirubin ≤ 2.0 mg/dL. <BR>                        In both studies, patients in the REVLIMID/dexamethasone group took 25 mg of REVLIMID orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle. Patients in the placebo/dexamethasone group took 1 placebo capsule on Days 1 to 28 of each 28-day cycle. Patients in both treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. <BR>                        The dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 of each 28-day cycle after the first 4 cycles of therapy. In both studies, treatment was to continue until disease progression.  <BR>                        In both studies, dose adjustments were allowed based on clinical and laboratory findings.   Sequential dose reductions to 15 mg daily, 10 mg daily and 5 mg daily were allowed for toxicity [see Dosage and Administration (2.1)]. <BR>                        Table 8 summarizes the baseline patient and disease characteristics in the two studies. In both studies, baseline demographic and disease-related characteristics were comparable between the REVLIMID/dexamethasone and placebo/dexamethasone groups.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="850"><BR>                           <caption>Table 8: Baseline Demographic and Disease-Related Characteristics &#8211; Studies 1 and 2</caption><BR>                           <tbody><BR>                              <tr><BR>                                 <td rowspan="2" styleCode="Lrule Rrule Botrule"/><BR>                                 <td colspan="2" align="center" styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Study 1</content><BR>                                 </td><BR>                                 <td colspan="2" align="center" styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Study 2</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">REVLIMID/Dex<br/>N=177</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Placebo/Dex<br/>N=176</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">REVLIMID/Dex<br/>N=176</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Placebo/Dex<br/>N=175</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Patient Characteristics</content><BR>                                 </td><BR>                                 <td colspan="4" styleCode="Lrule Rrule Botrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Age (years)</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Median</td><BR>                                 <td align="center" styleCode="Lrule Rrule">64</td><BR>                                 <td align="center" styleCode="Lrule Rrule">62</td><BR>                                 <td align="center" styleCode="Lrule Rrule">63</td><BR>                                 <td align="center" styleCode="Lrule Rrule">64</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">&#160;&#160;Min, Max</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">36, 86</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">37, 85</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">33, 84</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">40, 82</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Sex</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Male</td><BR>                                 <td align="center" styleCode="Lrule Rrule">106 (60%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule">104 (59%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule">104 (59%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule">103 (59%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">&#160;&#160;Female</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">  71 (40%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">  72 (41%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">  72 (41%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">  72 (41%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Race/Ethnicity</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;White</td><BR>                                 <td align="center" styleCode="Lrule Rrule">141(80%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule">148 (84%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule">172 (98%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule">175(100%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">&#160;&#160;Other</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">  36 (20%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">  28 (16%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">   4  (2%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">     0   (0%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">ECOG Performance        </td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">Status 0-1</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">157 (89%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">168 (95%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">150 (85%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">144 (82%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Disease Characteristics</content><BR>                                 </td><BR>                                 <td colspan="4" styleCode="Lrule Rrule Botrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Multiple Myeloma Stage (Durie-Salmon) </td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Rrule">I</td><BR>                                 <td align="center" styleCode="Lrule Rrule">3%</td><BR>                                 <td align="center" styleCode="Lrule Rrule">3%</td><BR>                                 <td align="center" styleCode="Lrule Rrule">6%</td><BR>                                 <td align="center" styleCode="Lrule Rrule">5%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Rrule">II</td><BR>                                 <td align="center" styleCode="Lrule Rrule">32%</td><BR>                                 <td align="center" styleCode="Lrule Rrule">31%</td><BR>                                 <td align="center" styleCode="Lrule Rrule">28%</td><BR>                                 <td align="center" styleCode="Lrule Rrule">33%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">III</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">64%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">66%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">65%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">63%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">B2-microglobulin  (mg/L)</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;&#8804; 2.5 mg/L</td><BR>                                 <td align="center" styleCode="Lrule Rrule">52 (29%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule">51 (29%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule">51 (29%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule">48 (27%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">&#160;&#160;&gt; 2.5 mg/L</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">125 (71%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">125 (71%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">125 (71%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">127 (73%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Number of Prior Therapies</content><BR>                                 </td><BR>                                 <td colspan="4" styleCode="Lrule Rrule Botrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Rrule">1</td><BR>                                 <td align="center" styleCode="Lrule Rrule">38%</td><BR>                                 <td align="center" styleCode="Lrule Rrule">38%</td><BR>                                 <td align="center" styleCode="Lrule Rrule">32%</td><BR>                                 <td align="center" styleCode="Lrule Rrule">33%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">&#8805; 2</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">62%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">62%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">68%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">67%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Types of Prior Therapies</content><BR>                                 </td><BR>                                 <td colspan="4" styleCode="Lrule Rrule Botrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">Stem Cell Transplantation</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">62%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">61%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">55%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">54%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">Thalidomide</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">42%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">46%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">30%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">38%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">Dexamethasone </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">81%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">71%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">66%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">69%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">Bortezomib 	</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">11%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">11%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">5%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">4%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">Melphalan	</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">33%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">31%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">56%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">52%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">Doxorubicin </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">55%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">51%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">56%</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">57%</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>The primary efficacy endpoint in both studies was time to progression (TTP). TTP was defined as the time from randomization to the first occurrence of progressive disease. <BR>                        Preplanned interim analyses of both studies showed that the combination of REVLIMID/dexamethasone was significantly superior to dexamethasone alone for TTP.  The studies were unblinded to allow patients in the placebo/dexamethasone group to receive treatment with the REVLIMID/dexamethasone combination.  For both studies, the extended follow-up survival data with crossovers were analyzed. In study 1, the median survival time was 39.4 months (95%CI: 32.9, 47.4) in REVLIMID/dexamethasone group and 31.6 months (95%CI: 24.1, 40.9) in placebo/dexamethasone group, with a hazard ratio of 0.79 (95% CI: 0.61-1.03). In study 2, the median survival time was 37.5 months (95%CI: 29.9, 46.6) in REVLIMID/dexamethasone group and 30.8 months (95%CI: 23.5, 40.3) in placebo/dexamethasone group, with a hazard ratio of 0.86 (95% CI: 0.65-1.14).<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="850"><BR>                           <caption>Table 9. TTP Results in Study 1 and Study 2</caption><BR>                           <tbody><BR>                              <tr><BR>                                 <td rowspan="2" styleCode="Lrule Rrule Botrule"/><BR>                                 <td colspan="2" align="center" styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Study 1</content><BR>                                 </td><BR>                                 <td colspan="2" align="center" styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Study 2</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">REVLIMID/Dex<br/>N=177</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Placebo/Dex<br/>N=176</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">REVLIMID/Dex<br/>N=176</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Placebo/Dex<br/>N=175</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">TTP </content><BR>                                 </td><BR>                                 <td colspan="4" styleCode="Lrule Rrule Botrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">Events n (%) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">73 (41) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">120 (68) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">68 (39) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">130 (74) </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Median TTP in months<br/>[95% CI] </td><BR>                                 <td align="center" styleCode="Lrule Rrule">13.9<br/>[9.5, 18.5]</td><BR>                                 <td align="center" styleCode="Lrule Rrule">4.7<br/>[3.7, 4.9]</td><BR>                                 <td align="center" styleCode="Lrule Rrule">12.1<br/>[9.5, NE]</td><BR>                                 <td align="center" styleCode="Lrule Rrule">4.7<br/>[3.8, 4.8]</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule Botrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule Botrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule Botrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule Botrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">Hazard Ratio<br/>[95% CI]</td><BR>                                 <td align="center" colspan="2" styleCode="Lrule Rrule Botrule">0.285<br/>[0.210, 0.386]</td><BR>                                 <td align="center" colspan="2" styleCode="Lrule Rrule Botrule">0.324<br/>[0.240, 0.438]</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td>&#160;</td><BR>                                 <td styleCode="Rrule">&#160;</td><BR>                                 <td>&#160;</td><BR>                                 <td styleCode="Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Log-rank Test p-value <sub>3</sub><BR>                                 </td><BR>                                 <td>&#160;</td><BR>                                 <td styleCode="Rrule">&#160;</td><BR>                                 <td>&#160;</td><BR>                                 <td styleCode="Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">&#160;</td><BR>                                 <td align="center" colspan="2" styleCode="Lrule Rrule Botrule">&lt;0.001 </td><BR>                                 <td align="center" colspan="2" styleCode="Lrule Rrule Botrule">&lt;0.001 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule"><BR>                                    <content styleCode="bold">Response </content><BR>                                 </td><BR>                                 <td colspan="4" styleCode="Lrule Rrule Botrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Complete Response</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">(CR) n (%)</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">23 (13) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">1 (1) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">27 (15) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">7 (4) </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Partial Response</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">(RR/PR) n (%) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">84 (48) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">33 (19) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">77 (44) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">34 (19) </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Overall Response n (%) </td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                                 <td styleCode="Lrule Rrule">&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">&#160;</td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">107 (61) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">34 (19) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">104 (59) </td><BR>                                 <td align="center" styleCode="Lrule Rrule Botrule">41 (23) </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">p-value </td><BR>                                 <td align="center" colspan="2" styleCode="Lrule Rrule Botrule">&lt;0.001 </td><BR>                                 <td align="center" colspan="2" styleCode="Lrule Rrule Botrule">&lt;0.001 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule Botrule">Odds Ratio [95% CI] </td><BR>                                 <td align="center" colspan="2" styleCode="Lrule Rrule Botrule">6.38<br/>[3.95, 10.32] </td><BR>                                 <td align="center" colspan="2" styleCode="Lrule Rrule Botrule">4.72<br/>[2.98, 7.49]</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           Figure 1:	Kaplan-Meier Estimate of Time to Progression — Study 1<BR>                        <BR>                        <BR>                           <BR>                        <BR>                        <BR>                           Figure 2:	Kaplan-Meier Estimate of Time to Progression — Study 2<BR>                        <BR>                        <BR>                           <BR>                        <BR>                        <BR>                     <BR>                     <BR>                     <BR>                        <BR>                           Figure 1:	Kaplan-Meier Estimate of Time to Progression — Study 1<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           Figure 2:	Kaplan-Meier Estimate of Time to Progression — Study 2<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.2.	Myelodysplastic Syndromes (MDS) with a Deletion 5q Cytogenetic Abnormality <BR>                     <BR>                        The efficacy and safety of REVLIMID were evaluated in patients with transfusion-dependent anemia in low- or intermediate-1- risk MDS with a 5q (q31-33) cytogenetic abnormality in isolation or with additional cytogenetic abnormalities, at a dose of 10 mg once daily or 10 mg once daily for 21 days every 28 days in an open-label, single-arm, multi-center study. The major study was not designed nor powered to prospectively compare the efficacy of the 2 dosing regimens. Sequential dose reductions to 5 mg daily and 5 mg every other day, as well as dose delays, were allowed for toxicity [Dosage and Administration (2.2)].  <BR>                        This major study enrolled 148 patients who had RBC transfusion dependent anemia. RBC transfusion dependence was defined as having received ≥ 2 units of RBCs within 8 weeks prior to study treatment. The study enrolled patients with absolute neutrophil counts (ANC) ≥ 500/mm3, platelet counts ≥ 50,000/mm3, serum creatinine ≤ 2.5 mg/dL, serum SGOT/AST or SGPT/ALT ≤ 3.0 x upper limit of normal (ULN), and serum direct bilirubin ≤ 2.0 mg/dL. Granulocyte colony-stimulating factor was permitted for patients who developed neutropenia or fever in association with neutropenia. Baseline patient and disease-related characteristics are summarized in Table 10.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="800"><BR>                           <caption>Table 10: Baseline Demographic and Disease-Related Characteristics in the MDS Study</caption><BR>                           <tfoot><BR>                              <tr><BR>                                 <td colspan="3"><BR>                                    <sup>[a]</sup> IPSS Risk Category: Low (combined score = 0), Intermediate-1 (combined score = 0.5 to 1.0), Intermediate-2 (combined score = 1.5 to 2.0), High (combined score &#8805; 2.5); Combined score = (Marrow blast score + Karyotype score + Cytopenia score)<br/><BR>                                    <sup>[b]</sup> French-American-British (FAB) classification of MDS.  </td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr><BR>                                 <th styleCode="Botrule Lrule">&#160;</th><BR>                                 <td colspan="2" align="center" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">Overall<br/>(N=148)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td colspan="3" styleCode="Botrule Lrule Rrule"><BR>                                    <content styleCode="bold"> Age (years)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Median</td><BR>                                 <td colspan="2" align="center" styleCode="Rrule">71.0</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule">&#160;&#160;Min, Max</td><BR>                                 <td colspan="2" align="center" styleCode="Botrule Rrule">37.0, 95.0</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule"><BR>                                    <content styleCode="bold"> Gender  </content><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule"><BR>                                    <content styleCode="bold">n</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule"> &#160;&#160;Male</td><BR>                                 <td align="center">51</td><BR>                                 <td align="center" styleCode="Rrule">(34.5)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule">&#160;&#160;Female</td><BR>                                 <td align="center" styleCode="Botrule">97</td><BR>                                 <td align="center" styleCode="Botrule Rrule">(65.5)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule"><BR>                                    <content styleCode="bold"> Race</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule"><BR>                                    <content styleCode="bold">n</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;White</td><BR>                                 <td align="center">143</td><BR>                                 <td align="center" styleCode="Rrule">(96.6)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule">&#160;&#160;Other</td><BR>                                 <td align="center" styleCode="Botrule">5</td><BR>                                 <td align="center" styleCode="Botrule Rrule">(3.4)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td colspan="3" styleCode="Botrule Lrule Rrule"><BR>                                    <content styleCode="bold"> Duration of MDS (years)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Median</td><BR>                                 <td align="center" colspan="2" styleCode="Rrule">2.5</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule">&#160;&#160;Min, Max</td><BR>                                 <td align="center" colspan="2" styleCode="Botrule Rrule">0.1, 20.7</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule"><BR>                                    <content styleCode="bold"> Del 5 (q31-33) Cytogenetic Abnormality  </content><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule"><BR>                                    <content styleCode="bold">n</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Yes</td><BR>                                 <td align="center">148</td><BR>                                 <td align="center" styleCode="Rrule">(100.0)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule">&#160;&#160;Other cytogenetic abnormalities</td><BR>                                 <td align="center" styleCode="Botrule">37</td><BR>                                 <td align="center" styleCode="Botrule Rrule">(25.2)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule"><BR>                                    <content styleCode="bold"> IPSS Score <sup>[a]</sup><BR>                                    </content><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule"><BR>                                    <content styleCode="bold">n</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Low (0)</td><BR>                                 <td align="center">55</td><BR>                                 <td align="center" styleCode="Rrule">(37.2)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Intermediate-1  (0.5-1.0)</td><BR>                                 <td align="center">65</td><BR>                                 <td align="center" styleCode="Rrule">(43.9)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;Intermediate-2  (1.5-2.0)</td><BR>                                 <td align="center">6</td><BR>                                 <td align="center" styleCode="Rrule">(4.1)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;High (&#8805;2.5)</td><BR>                                 <td align="center">2</td><BR>                                 <td align="center" styleCode="Rrule">(1.4)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule">&#160;&#160;Missing</td><BR>                                 <td align="center" styleCode="Botrule">20</td><BR>                                 <td align="center" styleCode="Botrule Rrule">(13.5)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule"><BR>                                    <content styleCode="bold"> FAB Classification <sup>[b]</sup> from central review</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule"><BR>                                    <content styleCode="bold">n</content><BR>                                 </td><BR>                                 <td align="center" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;RA</td><BR>                                 <td align="center">77</td><BR>                                 <td align="center" styleCode="Rrule">(52.0)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;RARS</td><BR>                                 <td align="center">16</td><BR>                                 <td align="center" styleCode="Rrule">(10.8)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule">&#160;&#160;RAEB</td><BR>                                 <td align="center">30</td><BR>                                 <td align="center" styleCode="Rrule">(20.3)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Botrule">&#160;&#160;CMML</td><BR>                                 <td align="center" styleCode="Botrule">3</td><BR>                                 <td align="center" styleCode="Botrule Rrule">(2.0)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>The frequency of RBC transfusion independence was assessed using criteria modified from the International Working Group (IWG) response criteria for MDS.  RBC transfusion independence was defined as the absence of any RBC transfusion during any consecutive “rolling” 56 days (8 weeks) during the treatment period.<BR>                        Transfusion independence was seen in 99/148 (67%) patients (95% CI [59, 74]). The median duration from the date when RBC transfusion independence was first declared (i.e., the last day of the 56-day RBC transfusion-free period) to the date when an additional transfusion was received after the 56-day transfusion-free period among the 99 responders was 44 weeks (range of 0 to >67 weeks).  Ninety percent of patients who achieved a transfusion benefit did so by completion of three months in the study.<BR>                        RBC transfusion independence rates were unaffected by age or gender.<BR>                        The dose of REVLIMID was reduced or interrupted at least once due to an adverse event in 118 (79.7%) of the 148 patients; the median time to the first dose reduction or interruption was 21 days (mean, 35.1 days; range, 2-253 days), and the median duration of the first dose interruption was 22 days (mean, 28.5 days; range, 2-265 days). A second dose reduction or interruption due to adverse events was required in 50 (33.8%) of the 148 patients. The median interval between the first and second dose reduction or interruption was 51 days (mean, 59.7 days; range, 15-205 days) and the median duration of the second dose interruption was 21 days (mean, 26 days; range, 2-148 days).<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>